About Centessa Pharmaceuticals
Centessa Pharmaceuticals is a company based in Boston (United States) founded in 2021.. Centessa Pharmaceuticals has raised $250 million across 1 funding round from investors including T. Rowe Price, General Atlantic and Janus Henderson Investors. The company has 77 employees as of December 31, 2024. Centessa Pharmaceuticals has completed 1 acquisition, including Apcintex. Centessa Pharmaceuticals offers products and services including Orexin Receptor 2 Agonist Program and LockBody Technology Platform. Centessa Pharmaceuticals operates in a competitive market with competitors including Actelion, Biogen, ADMA Biologics, Kymeratx and BioNTech, among others.
- Headquarter Boston, United States
- Employees 77 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Centessa Pharmaceuticals Plc Adr
-
Annual Revenue
$0-100as on Dec 31, 2024
-
Net Profit
$-235.86 M-55.51as on Dec 31, 2024
-
EBITDA
$-200.2 M-16.98as on Dec 31, 2024
-
Total Equity Funding
$250 M (USD)
in 1 rounds
-
Latest Funding Round
$250 M (USD), Series A
Feb 16, 2021
-
Investors
T. Rowe Price
& 13 more
-
Employee Count
77
as on Dec 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Centessa Pharmaceuticals
Centessa Pharmaceuticals is a publicly listed company on the NASDAQ with ticker symbol CNTA in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Centessa Pharmaceuticals
Centessa Pharmaceuticals offers a comprehensive portfolio of products and services, including Orexin Receptor 2 Agonist Program and LockBody Technology Platform. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Develops agonists for treating sleep-wake and neurological disorders
Enables innovative medicine development for various disorders
Unlock access to complete
Unlock access to complete
Funding Insights of Centessa Pharmaceuticals
Centessa Pharmaceuticals has successfully raised a total of $250M through 1 strategic funding round. The most recent funding activity was a Series A round of $250 million completed in February 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 1
- Last Round Series A — $250.0M
-
First Round
First Round
(16 Feb 2021)
- Investors Count 14
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb, 2021 | Amount | Series A - Centessa Pharmaceuticals | Valuation | General Atlantic , Vida Ventures |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Centessa Pharmaceuticals
Centessa Pharmaceuticals has secured backing from 14 investors, including venture fund and institutional investors. Prominent investors backing the company include T. Rowe Price, General Atlantic and Janus Henderson Investors. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity fund focused on global markets
|
Founded Year | Domain | Location | |
|
Biomedical innovations are transformed into therapies by Vida Ventures.
|
Founded Year | Domain | Location | |
|
Multiple sectors are targeted for venture capital investments.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Centessa Pharmaceuticals
Centessa Pharmaceuticals has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Apcintex. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Anti-coagulant targeting APC pathway is developed for haemophilia treatment.
|
2014 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Centessa Pharmaceuticals
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Centessa Pharmaceuticals Comparisons
Competitors of Centessa Pharmaceuticals
Centessa Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Actelion, Biogen, ADMA Biologics, Kymeratx and BioNTech, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Innovative treatments for orphan diseases are discovered, developed, and commercialized.
|
|
| domain | founded_year | HQ Location |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| domain | founded_year | HQ Location |
Plasma-based biologics are developed for immune deficiency and infectious diseases.
|
|
| domain | founded_year | HQ Location |
Small molecule protein degraders are developed for various disorders.
|
|
| domain | founded_year | HQ Location |
Immunotherapeutics for cancer and other diseases are developed.
|
|
| domain | founded_year | HQ Location |
Developer of novel protein-based therapeutics using machine learning and biological engineering
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Centessa Pharmaceuticals
Frequently Asked Questions about Centessa Pharmaceuticals
When was Centessa Pharmaceuticals founded?
Centessa Pharmaceuticals was founded in 2021.
Where is Centessa Pharmaceuticals located?
Centessa Pharmaceuticals is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Is Centessa Pharmaceuticals a funded company?
Centessa Pharmaceuticals is a funded company, having raised a total of $250M across 1 funding round to date. The company's 1st funding round was a Series A of $250M, raised on Feb 16, 2021.
How many employees does Centessa Pharmaceuticals have?
As of Dec 31, 2024, the latest employee count at Centessa Pharmaceuticals is 77.
What does Centessa Pharmaceuticals do?
Centessa Pharmaceuticals was founded in 2021 and is headquartered in Boston, United States. Medicines targeting sleep-wake disorders, neurological conditions, neurodegenerative diseases, and psychiatric issues are developed within the biotechnology sector. Operations encompass discovery through late-stage development of potential first-in-class and best-in-class therapies for rare diseases and immuno-oncology indications. Efforts are directed toward addressing unmet medical needs across these areas.
Who are the top competitors of Centessa Pharmaceuticals?
Centessa Pharmaceuticals's top competitors include ADMA Biologics, BioNTech and Vera Therapeutics.
What products or services does Centessa Pharmaceuticals offer?
Centessa Pharmaceuticals offers Orexin Receptor 2 Agonist Program and LockBody Technology Platform.
Is Centessa Pharmaceuticals publicly traded?
Yes, Centessa Pharmaceuticals is publicly traded on NASDAQ under the ticker symbol CNTA.
How many acquisitions has Centessa Pharmaceuticals made?
Centessa Pharmaceuticals has made 1 acquisition, including Apcintex.
Who are Centessa Pharmaceuticals's investors?
Centessa Pharmaceuticals has 14 investors. Key investors include T. Rowe Price, General Atlantic, Janus Henderson Investors, Vida Ventures, and Boxer Capital.
What is Centessa Pharmaceuticals's ticker symbol?
The ticker symbol of Centessa Pharmaceuticals is CNTA on NASDAQ.